Clinical Trials Using Leucovorin Calcium

Clinical trials are research studies that involve people. The clinical trials on this list are studying Leucovorin Calcium. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 51-56 of 56

  • Nivolumab in Combination with Chemotherapy before Surgery in Treating Patients with Borderline Resectable Pancreatic Cancer

    This phase I / II trial studies how well nivolumab and combination chemotherapy work before surgery in treating patients with pancreatic cancer that could possibly be removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as fluorouracil, irinotecan hydrochloride, leucovorin calcium and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab in combination with chemotherapy before surgery may work better in treating patients with pancreatic cancer compared to chemotherapy alone.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • Radiation Therapy and Chemotherapy in Treating Patients with Stage I-IIIB Rectal Cancer

    This phase II trial studies how well patients with stage I-IIIB rectal cancer respond to a short course of radiation therapy followed by chemotherapy. Radiation therapy uses high energy beams to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as oxaliplatin, leucovorin, fluorouracil, and capecitabine work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. A combination of radiation therapy and chemotherapy may prevent patients from needing surgery, could delay their need for surgery, or may mean that they need less drastic surgery and could potentially avoid a permanent ostomy (a surgically created connection between the intestine and the abdominal wall that allows for elimination of stool).
    Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri

  • Entinostat and the FOLFOX Chemotherapy Regimen in Treating Patients with Metastatic Pancreatic Cancer

    This phase Ib trial studies the best dose of entinostat when given together with the standard of care FOLFOX chemotherapy regimen in treating patients with pancreatic cancer that has spread to other places in the body (metastatic). Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in the FOLFOX chemotherapy regimen, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving the standard FOLFOX regimen together with entinostat may work better in treating patients with pancreatic cancer compared to the FOLFOX regimen alone.
    Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania

  • Intensive Combination Chemotherapy in Treating Patients with Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

    This partially randomized phase II trial studies how well intensive combination chemotherapy works in treating patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such as daunorubicin hydrochloride, cyclophosphamide, vincristine sulfate, prednisone, leucovorin calcium, cytarabine, etoposide, and liposomal cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as rituximab, may induce changes in body’s immune system and may interfere with the ability of cancer cells to grow and spread. Biological therapies, such as mercaptopurine, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Dietary supplements, such as levocarnitine, may reduce the incidence of liver damage. Pegaspargase, methotrexate, dasatinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy with, rituximab, mercaptopurine, levocarnitine, pegaspargase, methotrexate, dasatinib and imatinib mesylate may be an effective treatment for acute lymphoblastic leukemia or lymphoblastic lymphoma.
    Location: 3 locations

  • Combination Chemotherapy with or without Rituximab in Treating Younger Patients with Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia

    This randomized phase II / III trial studies how well combination chemotherapy with or without rituximab works in treating younger patients with stage III-IV non-Hodgkin lymphoma or B-cell acute leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibody, such as rituximab, may block cancer growth in different ways by targeting certain cells. It is not yet known whether combination chemotherapy together with rituximab is more effective in treating patients with non-Hodgkin lymphoma or B-cell acute leukemia.
    Location: See Clinical Trials.gov

  • Lidocaine Hydrochloride in Preventing Oxaliplatin-Induced Peripheral Neuropathy in Patients with Stage III-IV Colorectal Cancer

    This randomized phase I / II trial studies the best dose and side effects of lidocaine hydrochloride and how well it works in preventing oxaliplatin-induced peripheral neuropathy in patients with stage III-IV colorectal cancer. Lidocaine hydrochloride may work by blocking the nerve damaging effects of oxaliplatin.
    Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri